Dissemin is shutting down on January 1st, 2025

Published in

Springer Nature [academic journals on nature.com], Blood Cancer Journal, 3(5), p. e292-e292, 2015

DOI: 10.1038/bcj.2015.13

Links

Tools

Export citation

Search in Google Scholar

Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia

Journal article published in 2015 by Y. Collette, Thomas Prébet ORCID, A. Goubard, J. Adélaïde, R. Castellano, N. Carbuccia, S. Garnier, A. Guille, C. Arnoulet, A. Charbonier, Mj J. Mozziconacci, D. Birnbaum, M. Chaffanet, N. Vey
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Tyrosine kinase inhibitor (TKI)-based targeted therapy has significantly modified the outcome for patients with chronic myeloid leukemia (CML) in chronic phase. However, resistance remains a major concern in blastic phase of CML and in Philadelphia chromosome positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). Second- and third-generation TKIs have been developed to overcome resistance to first generation drugs, but selecting the appropriate drug has become a challenge.Various tests are available to determine a patient’s disease status in CML including the mechanisms of resistance when involved, but clinical experience is limited in ALL, especially those with poorly defined ABL1 rearrangements. Here, we report a case ofALL associated with a t(1;9)(q24;q34) RCSD1-ABL1 rearrangement. We show how ex vivo drug response profiling (DRP) may help choose among various therapeutic options.